AngioDynamics Inc (ANGO) is set to announce its Q1 2025 earnings today, with analysts anticipating a report showing a loss of ($0.15) per share. For the fiscal year 2025, the company has issued guidance in the range of ($0.42) to ($0.38) EPS, reflecting its outlook for the upcoming period.

Expected Q1 Earning Report of AngioDynamics Inc:

Below are the expected Q1 earning of AngioDynamics.

• The company is projected to report an EPS of ($0.15) for this quarter.
• AngioDynamics’ FY25 guidance is set between ($0.42) and ($0.38) EPS, indicating cautious navigation of market conditions.

This forecast reflects the company’s broader evaluation in the medical instruments and supplies sector, highlighting both performance and future prospects.

Investing is all about making informed decisions, and now you can do it for less. Get 70% off Stock Target Advisor and start optimizing your portfolio today. Grab your discount now!

Stock Target Advisor’s Analysis on AngioDynamics Inc:

Stock Target Advisor’s analysis paints a cautious picture of AngioDynamics Inc, rating it as Bearish This rating is based on two positive signals and five negative signals. While analysts have an average target price of USD 13.40 for AngioDynamics over the next 12 months and rate it as a Strong Buy, Stock Target Advisor’s bearish stance suggests caution due to factors like negative cash flow and low earnings growth. The company’s stock has seen a modest change in its price, with a current value of USD 7.65 and a 1-year capital gain of 3.38%.

Conclusion:

With the upcoming earnings report, AngioDynamics Inc is facing significant scrutiny. Analysts’ expectation of a ($0.15) loss per share for this quarter and the company’s FY25 guidance of ($0.42) to ($0.38) EPS indicate that the company is in a phase of cautious financial management. The earnings announcement will provide more clarity on the company’s future direction and its ability to meet financial and market challenges.